Salas Wang LLC: A Securities, Litigation, and Immigration Law Firm

  • Home
  • About
    • Attorneys
      • Jeffrey M. Salas
      • John C. Wang
  • Practice Areas
    • Securities Arbitration & Litigation
    • Business Litigation
    • Immigration Law
  • Current Investigations
  • Services
    • Free Portfolio Review
    • Free Immigration Consultation
    • Business Litigation: Alternative Fee Arrangements
  • Blog
  • Contact
  • Estate Planning
  • Subscribe

Sanofi Upping its Bid for Genzyme?

January 15, 2011

Via the NY Times Dealbook Sanofi-Aventis (NYSE: ADR) may be raising its bid for Genzyme (GENZ) $7 per share.  This would result in a roughly $1.8 billion offer increase (outstanding shares x price).

Share

{ 0 comments… add one now }

Cancel reply

Leave a Comment

Previous post: Dropping Knowledge: What Exactly is Stock?

Next post: Is Apple and/or Steve Jobs Committing Securities Fraud?

  • News/Blog

    • Thrivent – Variable Annuity Investigation
    • Warren Resources Investigation
    • Linn Energy Investigation
    • Oppenheimer Investigation
    • LPL Hit with Fines over Non-Traded REIT Sales
  • Recent Investigations

    • Thrivent - Variable Annuity Investigation
    • Linn Energy Investigation
    • Oppenheimer Investigation
    • LPL Hit with Fines over Non-Traded REIT Sales
    • Alton Securities Group Investigation
  • Immigration News

    • State of the Union Promises Immigration Reform
    • A Glimmer of Hope for Some Undocumented Immigrants?
    • Looking for H-1B Visas?
    • Employment Based Immigration
    • Family Based Immigration: Becoming a Legal Permanent Resident
  • Like Salas Wang LLC on Facebook/Follow Salas Wang LLC on Twitter

    Super Lawyers
    Jeffrey M. Salas
    visit superlawyers.com
  • Privacy Policy

Get smart with the Thesis WordPress Theme from DIYthemes.

Speak to an Attorney